Last reviewed · How we verify
SCB-2019 with AS03 adjuvant
At a glance
| Generic name | SCB-2019 with AS03 adjuvant |
|---|---|
| Sponsor | Clover Biopharmaceuticals AUS Pty |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SCB-2019 as COVID-19 Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCB-2019 with AS03 adjuvant CI brief — competitive landscape report
- SCB-2019 with AS03 adjuvant updates RSS · CI watch RSS
- Clover Biopharmaceuticals AUS Pty portfolio CI